A law that comes into effect next year will squeeze profits from moderately priced drugs that treat common, chronic conditions and increase economic incentives to develop high priced medicines for rare or acute life-threatening diseases. Manufacturers of drugs to treat common, chronic conditions will be especially hard hit.
read full article ›